| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metal Nanoparticles | 11 | 2024 | 164 | 3.000 |
Why?
|
| Pancreatic Neoplasms | 27 | 2024 | 5061 | 2.280 |
Why?
|
| Gold | 15 | 2024 | 270 | 2.230 |
Why?
|
| Radiation-Sensitizing Agents | 9 | 2019 | 363 | 2.110 |
Why?
|
| Lymphopenia | 5 | 2019 | 199 | 1.910 |
Why?
|
| Nanotubes | 3 | 2022 | 28 | 1.790 |
Why?
|
| Chemoradiotherapy | 18 | 2021 | 1946 | 1.690 |
Why?
|
| Carcinoma, Hepatocellular | 14 | 2023 | 2027 | 1.630 |
Why?
|
| Liver Neoplasms | 17 | 2023 | 4557 | 1.420 |
Why?
|
| Rectal Neoplasms | 17 | 2021 | 1202 | 1.330 |
Why?
|
| Radiation Injuries | 7 | 2023 | 1411 | 1.210 |
Why?
|
| Spleen | 2 | 2019 | 676 | 1.090 |
Why?
|
| Organs at Risk | 3 | 2019 | 514 | 1.070 |
Why?
|
| Gamma Rays | 3 | 2019 | 242 | 0.950 |
Why?
|
| Neoplasms | 14 | 2022 | 15193 | 0.900 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 8 | 2021 | 2370 | 0.850 |
Why?
|
| Contrast Media | 5 | 2021 | 1472 | 0.840 |
Why?
|
| Graphite | 2 | 2019 | 15 | 0.820 |
Why?
|
| Acidosis | 1 | 2022 | 116 | 0.810 |
Why?
|
| Nanotechnology | 2 | 2019 | 137 | 0.800 |
Why?
|
| Nanoparticles | 2 | 2019 | 554 | 0.770 |
Why?
|
| Immunotherapy | 8 | 2019 | 3341 | 0.760 |
Why?
|
| Hyperthermia, Induced | 5 | 2014 | 510 | 0.730 |
Why?
|
| Proton Therapy | 7 | 2023 | 1577 | 0.720 |
Why?
|
| Carcinoma, Pancreatic Ductal | 7 | 2022 | 1724 | 0.720 |
Why?
|
| Silver | 1 | 2019 | 34 | 0.720 |
Why?
|
| Combined Modality Therapy | 16 | 2021 | 8865 | 0.670 |
Why?
|
| Hydrolases | 1 | 2019 | 123 | 0.670 |
Why?
|
| Capecitabine | 10 | 2022 | 388 | 0.650 |
Why?
|
| Vascular System Injuries | 1 | 2018 | 52 | 0.640 |
Why?
|
| Drug Carriers | 1 | 2019 | 327 | 0.630 |
Why?
|
| Colorectal Neoplasms | 7 | 2022 | 3578 | 0.610 |
Why?
|
| Radiotherapy, Intensity-Modulated | 9 | 2019 | 2104 | 0.580 |
Why?
|
| Neoadjuvant Therapy | 19 | 2021 | 4975 | 0.580 |
Why?
|
| Dose-Response Relationship, Radiation | 6 | 2019 | 726 | 0.580 |
Why?
|
| Radiotherapy | 9 | 2016 | 1824 | 0.570 |
Why?
|
| Deoxycytidine | 12 | 2022 | 1353 | 0.560 |
Why?
|
| Arginine | 1 | 2019 | 500 | 0.550 |
Why?
|
| Respiration | 2 | 2009 | 447 | 0.550 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 615 | 0.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 18 | 2022 | 15862 | 0.530 |
Why?
|
| Adenocarcinoma | 15 | 2020 | 7789 | 0.510 |
Why?
|
| Humans | 107 | 2023 | 261506 | 0.510 |
Why?
|
| Prostate | 2 | 2017 | 1088 | 0.510 |
Why?
|
| Mice | 30 | 2024 | 34495 | 0.510 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 589 | 0.500 |
Why?
|
| Sesquiterpenes | 1 | 2014 | 68 | 0.500 |
Why?
|
| Animals | 38 | 2024 | 59536 | 0.490 |
Why?
|
| Heart | 2 | 2019 | 1223 | 0.460 |
Why?
|
| Radiotherapy Dosage | 13 | 2023 | 3842 | 0.450 |
Why?
|
| Induction Chemotherapy | 5 | 2022 | 669 | 0.440 |
Why?
|
| Glutathione | 1 | 2014 | 368 | 0.430 |
Why?
|
| Lymphocyte Count | 3 | 2018 | 486 | 0.410 |
Why?
|
| Prostatic Neoplasms | 5 | 2017 | 5767 | 0.410 |
Why?
|
| Brachytherapy | 2 | 2017 | 977 | 0.400 |
Why?
|
| Male | 62 | 2020 | 123000 | 0.390 |
Why?
|
| Radiation Dosage | 5 | 2018 | 1014 | 0.390 |
Why?
|
| Reactive Oxygen Species | 2 | 2019 | 987 | 0.390 |
Why?
|
| Radiotherapy, Image-Guided | 3 | 2019 | 304 | 0.390 |
Why?
|
| Cell Line, Tumor | 18 | 2022 | 14551 | 0.370 |
Why?
|
| Bile Duct Neoplasms | 4 | 2018 | 493 | 0.360 |
Why?
|
| Middle Aged | 48 | 2020 | 86204 | 0.320 |
Why?
|
| Female | 58 | 2021 | 141928 | 0.320 |
Why?
|
| Fluorouracil | 9 | 2016 | 1944 | 0.320 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2016 | 690 | 0.320 |
Why?
|
| DNA Repair | 3 | 2017 | 1872 | 0.320 |
Why?
|
| Aged | 41 | 2020 | 70117 | 0.320 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 442 | 0.310 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2021 | 3821 | 0.310 |
Why?
|
| Breath Holding | 2 | 2019 | 44 | 0.310 |
Why?
|
| Triiodobenzoic Acids | 1 | 2008 | 68 | 0.310 |
Why?
|
| Apoptosis | 9 | 2019 | 7591 | 0.310 |
Why?
|
| Treatment Outcome | 24 | 2019 | 32848 | 0.310 |
Why?
|
| Aged, 80 and over | 23 | 2020 | 29902 | 0.310 |
Why?
|
| Anus Neoplasms | 3 | 2018 | 411 | 0.290 |
Why?
|
| X-Rays | 2 | 2017 | 146 | 0.290 |
Why?
|
| Cholangiocarcinoma | 4 | 2018 | 493 | 0.290 |
Why?
|
| Fatigue | 2 | 2012 | 1239 | 0.280 |
Why?
|
| Radiographic Image Enhancement | 2 | 2008 | 402 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2021 | 10035 | 0.270 |
Why?
|
| ErbB Receptors | 4 | 2012 | 2295 | 0.260 |
Why?
|
| Neoplasm Staging | 16 | 2021 | 13658 | 0.260 |
Why?
|
| Esophageal Neoplasms | 5 | 2019 | 3168 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 2 | 2023 | 84 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2018 | 7551 | 0.250 |
Why?
|
| Particle Accelerators | 2 | 2021 | 352 | 0.250 |
Why?
|
| Disease-Free Survival | 12 | 2017 | 10001 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2019 | 6207 | 0.240 |
Why?
|
| Signal Transduction | 6 | 2016 | 11965 | 0.230 |
Why?
|
| Aorta | 2 | 2018 | 692 | 0.230 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 7222 | 0.230 |
Why?
|
| Liver | 4 | 2019 | 2961 | 0.220 |
Why?
|
| Cell Proliferation | 9 | 2019 | 7226 | 0.220 |
Why?
|
| Cathepsin B | 1 | 2022 | 32 | 0.220 |
Why?
|
| Adult | 32 | 2020 | 77950 | 0.220 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2017 | 565 | 0.220 |
Why?
|
| Pancreatectomy | 3 | 2018 | 652 | 0.220 |
Why?
|
| Survival Analysis | 10 | 2018 | 9180 | 0.220 |
Why?
|
| Quinazolines | 2 | 2013 | 923 | 0.220 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2016 | 388 | 0.210 |
Why?
|
| CD47 Antigen | 1 | 2022 | 26 | 0.210 |
Why?
|
| Nanoshells | 2 | 2013 | 43 | 0.210 |
Why?
|
| Triterpenes | 2 | 2012 | 61 | 0.210 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 2864 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2021 | 7702 | 0.200 |
Why?
|
| Biomarkers, Tumor | 8 | 2017 | 10331 | 0.200 |
Why?
|
| Mice, Nude | 8 | 2017 | 4307 | 0.200 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2023 | 160 | 0.200 |
Why?
|
| Preoperative Care | 5 | 2016 | 1529 | 0.200 |
Why?
|
| Nanotubes, Carbon | 2 | 2011 | 29 | 0.200 |
Why?
|
| Retrospective Studies | 24 | 2023 | 37905 | 0.200 |
Why?
|
| Albumins | 1 | 2022 | 258 | 0.190 |
Why?
|
| Glutamic Acid | 1 | 2022 | 309 | 0.190 |
Why?
|
| Maximum Tolerated Dose | 3 | 2016 | 1290 | 0.190 |
Why?
|
| Lysine | 1 | 2022 | 422 | 0.190 |
Why?
|
| Radiotherapy, Conformal | 3 | 2016 | 902 | 0.180 |
Why?
|
| Disease Progression | 5 | 2019 | 6682 | 0.180 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2021 | 295 | 0.180 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2019 | 202 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 630 | 0.180 |
Why?
|
| Quantum Dots | 1 | 2019 | 30 | 0.180 |
Why?
|
| Hypoxia | 1 | 2022 | 443 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 152 | 0.180 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2021 | 324 | 0.180 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 269 | 0.180 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2012 | 1299 | 0.180 |
Why?
|
| Photosensitizing Agents | 1 | 2019 | 71 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2018 | 5437 | 0.180 |
Why?
|
| Neoplasm Metastasis | 6 | 2019 | 5112 | 0.170 |
Why?
|
| Ion Transport | 1 | 1999 | 79 | 0.170 |
Why?
|
| Survival Rate | 8 | 2019 | 12221 | 0.170 |
Why?
|
| Exotoxins | 1 | 1999 | 77 | 0.170 |
Why?
|
| Prognosis | 11 | 2019 | 21713 | 0.170 |
Why?
|
| Biomarkers | 2 | 2022 | 5047 | 0.170 |
Why?
|
| Sodium Chloride | 1 | 1999 | 156 | 0.170 |
Why?
|
| Light | 1 | 2019 | 245 | 0.170 |
Why?
|
| Colon | 2 | 2000 | 670 | 0.170 |
Why?
|
| Ions | 2 | 2024 | 53 | 0.160 |
Why?
|
| Erbium | 1 | 2017 | 2 | 0.160 |
Why?
|
| Fatty Acids, Volatile | 1 | 1998 | 52 | 0.160 |
Why?
|
| Protons | 2 | 2023 | 473 | 0.160 |
Why?
|
| Radiosurgery | 3 | 2016 | 1330 | 0.160 |
Why?
|
| Starch | 1 | 1998 | 47 | 0.160 |
Why?
|
| Bacterial Toxins | 1 | 1999 | 228 | 0.160 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2019 | 226 | 0.150 |
Why?
|
| Histological Techniques | 1 | 2017 | 65 | 0.150 |
Why?
|
| Cell Death | 1 | 2019 | 671 | 0.150 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2017 | 93 | 0.150 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 122 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 8 | 1 | 2016 | 17 | 0.150 |
Why?
|
| Breast Neoplasms | 4 | 2021 | 15694 | 0.150 |
Why?
|
| Bevacizumab | 3 | 2016 | 938 | 0.150 |
Why?
|
| Argininosuccinate Synthase | 1 | 2017 | 54 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2022 | 1048 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 2314 | 0.140 |
Why?
|
| Homologous Recombination | 1 | 2017 | 185 | 0.140 |
Why?
|
| E2F Transcription Factors | 1 | 2016 | 132 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2017 | 64 | 0.140 |
Why?
|
| HCT116 Cells | 2 | 2014 | 348 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2023 | 1648 | 0.140 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2016 | 6 | 0.140 |
Why?
|
| Nelfinavir | 1 | 2016 | 15 | 0.140 |
Why?
|
| Gallbladder Neoplasms | 2 | 2016 | 245 | 0.140 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 4988 | 0.140 |
Why?
|
| Flavonoids | 1 | 2017 | 188 | 0.140 |
Why?
|
| Tumor Burden | 3 | 2020 | 1987 | 0.140 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 99 | 0.140 |
Why?
|
| Carotid Arteries | 1 | 2017 | 240 | 0.140 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 671 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 657 | 0.130 |
Why?
|
| Neoplasms, Experimental | 2 | 2016 | 750 | 0.130 |
Why?
|
| Histone Deacetylases | 1 | 2017 | 365 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 467 | 0.130 |
Why?
|
| Interferon Type I | 1 | 2016 | 250 | 0.130 |
Why?
|
| Goserelin | 1 | 2015 | 18 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2022 | 1996 | 0.130 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 335 | 0.130 |
Why?
|
| Glioblastoma | 1 | 2006 | 1797 | 0.130 |
Why?
|
| Metabolomics | 1 | 2018 | 478 | 0.130 |
Why?
|
| beta Catenin | 2 | 2016 | 688 | 0.130 |
Why?
|
| Re-Irradiation | 1 | 2017 | 163 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2020 | 524 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2023 | 935 | 0.130 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 14889 | 0.130 |
Why?
|
| HT29 Cells | 1 | 2014 | 159 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2020 | 3890 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2019 | 1234 | 0.120 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 14289 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 268 | 0.120 |
Why?
|
| Photons | 1 | 2017 | 507 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 550 | 0.120 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 206 | 0.120 |
Why?
|
| Diarrhea | 1 | 1998 | 686 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 5395 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 697 | 0.120 |
Why?
|
| Stomach Neoplasms | 3 | 2012 | 2278 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2019 | 574 | 0.120 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 1022 | 0.110 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2015 | 167 | 0.110 |
Why?
|
| Radiometry | 1 | 2019 | 980 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 1011 | 0.110 |
Why?
|
| Carcinoma | 2 | 2017 | 2578 | 0.110 |
Why?
|
| Lipocalins | 2 | 2013 | 54 | 0.110 |
Why?
|
| CA-19-9 Antigen | 1 | 2013 | 144 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 1547 | 0.110 |
Why?
|
| Acute-Phase Proteins | 2 | 2013 | 79 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2020 | 5542 | 0.110 |
Why?
|
| Logistic Models | 2 | 2018 | 3441 | 0.110 |
Why?
|
| Inflammation | 4 | 2023 | 2522 | 0.110 |
Why?
|
| Time Factors | 5 | 2016 | 12926 | 0.110 |
Why?
|
| Pacemaker, Artificial | 1 | 2015 | 213 | 0.110 |
Why?
|
| Radiation Tolerance | 2 | 2019 | 629 | 0.110 |
Why?
|
| Defibrillators, Implantable | 1 | 2015 | 221 | 0.110 |
Why?
|
| Dilatation | 1 | 2012 | 83 | 0.110 |
Why?
|
| NF-kappa B | 4 | 2012 | 1549 | 0.100 |
Why?
|
| Genitalia, Female | 1 | 2012 | 68 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 77 | 0.100 |
Why?
|
| Duodenum | 1 | 2012 | 149 | 0.100 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 1215 | 0.100 |
Why?
|
| Piperidines | 1 | 2017 | 1035 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2016 | 2316 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 6942 | 0.100 |
Why?
|
| Barrett Esophagus | 1 | 2017 | 569 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 1904 | 0.100 |
Why?
|
| Ferric Compounds | 1 | 2011 | 73 | 0.100 |
Why?
|
| Radiation Protection | 1 | 2012 | 205 | 0.100 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 598 | 0.100 |
Why?
|
| Carbon | 1 | 2011 | 149 | 0.100 |
Why?
|
| Chromans | 1 | 2010 | 31 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4298 | 0.090 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 191 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2013 | 4849 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2017 | 8873 | 0.090 |
Why?
|
| Vitamin E | 1 | 2010 | 136 | 0.090 |
Why?
|
| Smad4 Protein | 1 | 2011 | 196 | 0.090 |
Why?
|
| Pancreas | 1 | 2013 | 718 | 0.090 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2012 | 275 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2011 | 215 | 0.090 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 189 | 0.090 |
Why?
|
| Protein Binding | 2 | 2010 | 3438 | 0.090 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2011 | 192 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2011 | 231 | 0.090 |
Why?
|
| Butyrates | 2 | 2000 | 57 | 0.080 |
Why?
|
| Sleep Stages | 1 | 2009 | 78 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2015 | 732 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2010 | 886 | 0.080 |
Why?
|
| Metformin | 1 | 2013 | 378 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2014 | 2084 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2020 | 2231 | 0.080 |
Why?
|
| Motion | 1 | 2009 | 193 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2021 | 4804 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 586 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1664 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2014 | 1129 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2010 | 396 | 0.080 |
Why?
|
| Rectum | 2 | 2021 | 467 | 0.080 |
Why?
|
| Sacrum | 1 | 2009 | 132 | 0.080 |
Why?
|
| Lymphatic Metastasis | 5 | 2020 | 4844 | 0.080 |
Why?
|
| Cell Survival | 2 | 2012 | 3045 | 0.080 |
Why?
|
| Genomics | 1 | 2018 | 2738 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1656 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2020 | 12873 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2009 | 132 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2012 | 1038 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 573 | 0.070 |
Why?
|
| Placebos | 1 | 2007 | 437 | 0.070 |
Why?
|
| DNA Damage | 1 | 2014 | 1954 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2330 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 600 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 612 | 0.070 |
Why?
|
| Remission Induction | 2 | 2011 | 3569 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 1999 | 1618 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 552 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 11538 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 4938 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2015 | 6869 | 0.070 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 334 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 2045 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 3552 | 0.070 |
Why?
|
| Immune System | 2 | 2019 | 279 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 2518 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2013 | 1154 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 1533 | 0.060 |
Why?
|
| Obesity | 1 | 2017 | 2884 | 0.060 |
Why?
|
| Intraoperative Care | 1 | 2006 | 259 | 0.060 |
Why?
|
| Movement | 1 | 2007 | 556 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 3981 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 882 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5178 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 1879 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2016 | 3251 | 0.060 |
Why?
|
| Pain | 2 | 2009 | 1658 | 0.060 |
Why?
|
| Histones | 1 | 2010 | 1466 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 852 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2023 | 252 | 0.060 |
Why?
|
| Ecosystem | 1 | 2024 | 111 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5319 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1362 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 1443 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2019 | 1546 | 0.050 |
Why?
|
| Antigens, Neoplasm | 2 | 2022 | 1506 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2015 | 2947 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2006 | 980 | 0.050 |
Why?
|
| Mammals | 1 | 2024 | 361 | 0.050 |
Why?
|
| Software | 1 | 2009 | 1321 | 0.050 |
Why?
|
| Ribose | 1 | 2021 | 32 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 4367 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2019 | 2307 | 0.050 |
Why?
|
| Hepatectomy | 2 | 2019 | 1011 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2021 | 113 | 0.050 |
Why?
|
| Lipocalin-2 | 2 | 2013 | 65 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 249 | 0.050 |
Why?
|
| Feedback | 1 | 2021 | 198 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 170 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 430 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2011 | 2967 | 0.050 |
Why?
|
| Ki-67 Antigen | 2 | 2012 | 666 | 0.050 |
Why?
|
| Standard of Care | 1 | 2021 | 243 | 0.050 |
Why?
|
| Shigella dysenteriae | 1 | 1999 | 3 | 0.040 |
Why?
|
| Shiga Toxins | 1 | 1999 | 5 | 0.040 |
Why?
|
| Young Adult | 4 | 2015 | 21445 | 0.040 |
Why?
|
| Lactic Acid | 2 | 2000 | 305 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 7548 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2021 | 621 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2008 | 2488 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2291 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 9244 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 6009 | 0.040 |
Why?
|
| Inflammation Mediators | 2 | 2012 | 423 | 0.040 |
Why?
|
| Intestinal Absorption | 1 | 1999 | 211 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2012 | 1313 | 0.040 |
Why?
|
| Organoplatinum Compounds | 2 | 2011 | 702 | 0.040 |
Why?
|
| Virus Activation | 1 | 2020 | 228 | 0.040 |
Why?
|
| Radioisotopes | 1 | 1999 | 177 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2019 | 207 | 0.040 |
Why?
|
| Butyric Acid | 1 | 1998 | 13 | 0.040 |
Why?
|
| Texas | 3 | 2015 | 6311 | 0.040 |
Why?
|
| Fermentation | 1 | 1998 | 60 | 0.040 |
Why?
|
| Necrosis | 1 | 2019 | 580 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 285 | 0.040 |
Why?
|
| Ascites | 1 | 2019 | 198 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 1999 | 562 | 0.040 |
Why?
|
| Cetuximab | 2 | 2011 | 472 | 0.040 |
Why?
|
| Risk Factors | 5 | 2015 | 17523 | 0.040 |
Why?
|
| Uncertainty | 1 | 2019 | 320 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 292 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2020 | 397 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 690 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2000 | 268 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2017 | 2203 | 0.040 |
Why?
|
| Fluorescence | 1 | 2017 | 195 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 1323 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 1020 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1519 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 3472 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 465 | 0.040 |
Why?
|
| Anal Canal | 1 | 2017 | 238 | 0.030 |
Why?
|
| Hepatitis B | 1 | 2019 | 258 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 117 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2017 | 181 | 0.030 |
Why?
|
| Equipment Design | 2 | 2012 | 1204 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2022 | 2450 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2017 | 275 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 235 | 0.030 |
Why?
|
| Niacinamide | 1 | 2017 | 421 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1869 | 0.030 |
Why?
|
| United States | 3 | 2020 | 15433 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2015 | 170 | 0.030 |
Why?
|
| Reoperation | 1 | 2020 | 1382 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2017 | 277 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 311 | 0.030 |
Why?
|
| Neutrons | 1 | 2015 | 117 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 663 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2019 | 1732 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 750 | 0.030 |
Why?
|
| Research Design | 2 | 2013 | 1544 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 4757 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 665 | 0.030 |
Why?
|
| Mitochondria | 1 | 2021 | 1282 | 0.030 |
Why?
|
| Benchmarking | 1 | 2016 | 273 | 0.030 |
Why?
|
| Electrons | 1 | 2015 | 168 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 85 | 0.030 |
Why?
|
| Glucose | 1 | 2000 | 1248 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2017 | 580 | 0.030 |
Why?
|
| Liposomes | 1 | 2015 | 684 | 0.030 |
Why?
|
| Magnets | 1 | 2013 | 32 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 2437 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 3536 | 0.030 |
Why?
|
| Macrophages | 1 | 2019 | 1304 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1271 | 0.030 |
Why?
|
| Phototherapy | 1 | 2013 | 75 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 694 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3639 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 1682 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2015 | 749 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2012 | 170 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2013 | 122 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 211 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2292 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 221 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 157 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 677 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 1271 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 548 | 0.030 |
Why?
|
| Optical Imaging | 1 | 2013 | 157 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 1408 | 0.030 |
Why?
|
| Boswellia | 1 | 2011 | 3 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 657 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 672 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 1998 | 1081 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2017 | 620 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 2011 | 159 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 354 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 992 | 0.030 |
Why?
|
| Dehydration | 1 | 2011 | 87 | 0.030 |
Why?
|
| Feeding and Eating Disorders | 1 | 2012 | 97 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 459 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2013 | 298 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1046 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2013 | 315 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 2216 | 0.020 |
Why?
|
| Anorexia | 1 | 2011 | 143 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2017 | 1026 | 0.020 |
Why?
|
| Ribonucleotide Reductases | 1 | 2010 | 51 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2020 | 6100 | 0.020 |
Why?
|
| Rats | 1 | 1999 | 6086 | 0.020 |
Why?
|
| Vagina | 1 | 2012 | 317 | 0.020 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 278 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 604 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6295 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2010 | 187 | 0.020 |
Why?
|
| Nausea | 1 | 2011 | 525 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2010 | 629 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 482 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 669 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 360 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 1586 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2011 | 451 | 0.020 |
Why?
|
| Endosonography | 1 | 2012 | 536 | 0.020 |
Why?
|
| Exhalation | 1 | 2008 | 60 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2009 | 129 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 316 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2008 | 72 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1082 | 0.020 |
Why?
|
| Sleep Wake Disorders | 1 | 2012 | 348 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2010 | 483 | 0.020 |
Why?
|
| Incidence | 2 | 2009 | 5673 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 967 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2016 | 1589 | 0.020 |
Why?
|
| Transcriptome | 1 | 2016 | 1859 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2016 | 1112 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 1225 | 0.020 |
Why?
|
| Muscles | 1 | 2008 | 416 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 103 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1945 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 566 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 1248 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 1544 | 0.020 |
Why?
|
| Iridium Radioisotopes | 1 | 2006 | 56 | 0.020 |
Why?
|
| Surface Properties | 1 | 2006 | 180 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 1121 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 1008 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 3719 | 0.020 |
Why?
|
| Artifacts | 1 | 2008 | 532 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3230 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 4892 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 1000 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 3890 | 0.020 |
Why?
|
| Radiology, Interventional | 1 | 2006 | 138 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5159 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 1823 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 2055 | 0.010 |
Why?
|
| Sex Factors | 1 | 2009 | 2139 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2008 | 769 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 1959 | 0.010 |
Why?
|
| Kidney | 1 | 2011 | 2146 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5539 | 0.010 |
Why?
|
| Cytokines | 1 | 2012 | 2809 | 0.010 |
Why?
|
| Recurrence | 1 | 2011 | 4758 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 4320 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 6150 | 0.010 |
Why?
|
| Dextran Sulfate | 1 | 2000 | 72 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 1301 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5637 | 0.010 |
Why?
|
| Palliative Care | 1 | 2011 | 2037 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 2173 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2000 | 717 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2010 | 3518 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 15179 | 0.010 |
Why?
|